Cargando…

Vaccines for maternal immunization against Group B Streptococcus disease: WHO perspectives on case ascertainment and case definitions

Group B Streptococcus (GBS) is an important cause of disease in young infants, stillbirths, pregnant and post-partum women. GBS vaccines for maternal immunization are in development aiming to reduce this burden. Standardisation of case definitions and ascertainment methodologies for GBS disease is n...

Descripción completa

Detalles Bibliográficos
Autores principales: Seale, Anna C., Baker, Carol J., Berkley, James A., Madhi, Shabir A., Ordi, Jaume, Saha, Samir K., Schrag, Stephanie J., Sobanjo-ter Meulen, Ajoke, Vekemans, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677922/
https://www.ncbi.nlm.nih.gov/pubmed/31303524
http://dx.doi.org/10.1016/j.vaccine.2019.07.012
_version_ 1783440982068428800
author Seale, Anna C.
Baker, Carol J.
Berkley, James A.
Madhi, Shabir A.
Ordi, Jaume
Saha, Samir K.
Schrag, Stephanie J.
Sobanjo-ter Meulen, Ajoke
Vekemans, Johan
author_facet Seale, Anna C.
Baker, Carol J.
Berkley, James A.
Madhi, Shabir A.
Ordi, Jaume
Saha, Samir K.
Schrag, Stephanie J.
Sobanjo-ter Meulen, Ajoke
Vekemans, Johan
author_sort Seale, Anna C.
collection PubMed
description Group B Streptococcus (GBS) is an important cause of disease in young infants, stillbirths, pregnant and post-partum women. GBS vaccines for maternal immunization are in development aiming to reduce this burden. Standardisation of case definitions and ascertainment methodologies for GBS disease is needed to support future trials of maternal GBS vaccines. Considerations presented here may also serve to promote consistency in observational studies and surveillance, to better establish disease burden. The World Health Organization convened a working group to provide consensus guidance for case ascertainment and case definitions of GBS disease in stillbirths, infants, pregnant and post-partum women, with feedback sought from external stakeholders. In intervention studies, case capture and case ascertainment for GBS disease should be based on antenatal recruitment of women, with active follow-up, systematic clinical assessment, standardised sampling strategies and optimised laboratory methods. Confirmed cases of invasive GBS disease in stillbirths or infants should be included in a primary composite endpoint for vaccine efficacy studies, with GBS cultured from a usually sterile body site (may be post-mortem). For additional endpoints, or observational studies, confirmed cases of GBS sepsis in pregnant and post-partum women should be assessed. Culture independent diagnostic tests (CIDTs) may detect additional presumed cases, however, the use of these diagnostics needs further evaluation. Efficacy of vaccination against maternal and neonatal GBS colonisation, and maternal GBS urinary tract infection could be included as additional, separate, endpoints and/or in observational studies. Whilst the focus here is on specific GBS disease outcomes, intervention studies also present an opportunity to establish the contribution of GBS across adverse perinatal outcomes, including all-cause stillbirth, preterm birth and neonatal encephalopathy.
format Online
Article
Text
id pubmed-6677922
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier Science
record_format MEDLINE/PubMed
spelling pubmed-66779222019-08-14 Vaccines for maternal immunization against Group B Streptococcus disease: WHO perspectives on case ascertainment and case definitions Seale, Anna C. Baker, Carol J. Berkley, James A. Madhi, Shabir A. Ordi, Jaume Saha, Samir K. Schrag, Stephanie J. Sobanjo-ter Meulen, Ajoke Vekemans, Johan Vaccine Article Group B Streptococcus (GBS) is an important cause of disease in young infants, stillbirths, pregnant and post-partum women. GBS vaccines for maternal immunization are in development aiming to reduce this burden. Standardisation of case definitions and ascertainment methodologies for GBS disease is needed to support future trials of maternal GBS vaccines. Considerations presented here may also serve to promote consistency in observational studies and surveillance, to better establish disease burden. The World Health Organization convened a working group to provide consensus guidance for case ascertainment and case definitions of GBS disease in stillbirths, infants, pregnant and post-partum women, with feedback sought from external stakeholders. In intervention studies, case capture and case ascertainment for GBS disease should be based on antenatal recruitment of women, with active follow-up, systematic clinical assessment, standardised sampling strategies and optimised laboratory methods. Confirmed cases of invasive GBS disease in stillbirths or infants should be included in a primary composite endpoint for vaccine efficacy studies, with GBS cultured from a usually sterile body site (may be post-mortem). For additional endpoints, or observational studies, confirmed cases of GBS sepsis in pregnant and post-partum women should be assessed. Culture independent diagnostic tests (CIDTs) may detect additional presumed cases, however, the use of these diagnostics needs further evaluation. Efficacy of vaccination against maternal and neonatal GBS colonisation, and maternal GBS urinary tract infection could be included as additional, separate, endpoints and/or in observational studies. Whilst the focus here is on specific GBS disease outcomes, intervention studies also present an opportunity to establish the contribution of GBS across adverse perinatal outcomes, including all-cause stillbirth, preterm birth and neonatal encephalopathy. Elsevier Science 2019-08-14 /pmc/articles/PMC6677922/ /pubmed/31303524 http://dx.doi.org/10.1016/j.vaccine.2019.07.012 Text en © 2019 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Seale, Anna C.
Baker, Carol J.
Berkley, James A.
Madhi, Shabir A.
Ordi, Jaume
Saha, Samir K.
Schrag, Stephanie J.
Sobanjo-ter Meulen, Ajoke
Vekemans, Johan
Vaccines for maternal immunization against Group B Streptococcus disease: WHO perspectives on case ascertainment and case definitions
title Vaccines for maternal immunization against Group B Streptococcus disease: WHO perspectives on case ascertainment and case definitions
title_full Vaccines for maternal immunization against Group B Streptococcus disease: WHO perspectives on case ascertainment and case definitions
title_fullStr Vaccines for maternal immunization against Group B Streptococcus disease: WHO perspectives on case ascertainment and case definitions
title_full_unstemmed Vaccines for maternal immunization against Group B Streptococcus disease: WHO perspectives on case ascertainment and case definitions
title_short Vaccines for maternal immunization against Group B Streptococcus disease: WHO perspectives on case ascertainment and case definitions
title_sort vaccines for maternal immunization against group b streptococcus disease: who perspectives on case ascertainment and case definitions
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677922/
https://www.ncbi.nlm.nih.gov/pubmed/31303524
http://dx.doi.org/10.1016/j.vaccine.2019.07.012
work_keys_str_mv AT sealeannac vaccinesformaternalimmunizationagainstgroupbstreptococcusdiseasewhoperspectivesoncaseascertainmentandcasedefinitions
AT bakercarolj vaccinesformaternalimmunizationagainstgroupbstreptococcusdiseasewhoperspectivesoncaseascertainmentandcasedefinitions
AT berkleyjamesa vaccinesformaternalimmunizationagainstgroupbstreptococcusdiseasewhoperspectivesoncaseascertainmentandcasedefinitions
AT madhishabira vaccinesformaternalimmunizationagainstgroupbstreptococcusdiseasewhoperspectivesoncaseascertainmentandcasedefinitions
AT ordijaume vaccinesformaternalimmunizationagainstgroupbstreptococcusdiseasewhoperspectivesoncaseascertainmentandcasedefinitions
AT sahasamirk vaccinesformaternalimmunizationagainstgroupbstreptococcusdiseasewhoperspectivesoncaseascertainmentandcasedefinitions
AT schragstephaniej vaccinesformaternalimmunizationagainstgroupbstreptococcusdiseasewhoperspectivesoncaseascertainmentandcasedefinitions
AT sobanjotermeulenajoke vaccinesformaternalimmunizationagainstgroupbstreptococcusdiseasewhoperspectivesoncaseascertainmentandcasedefinitions
AT vekemansjohan vaccinesformaternalimmunizationagainstgroupbstreptococcusdiseasewhoperspectivesoncaseascertainmentandcasedefinitions